Tech Company Financing Transactions
Croma Medicine Funding Round
On 3/1/2023, Croma Medicine landed $135 million in Series B funding from GV, Arch Venture Partners and DCVC Bio.
Transaction Overview
Company Name
Announced On
3/1/2023
Transaction Type
Venture Equity
Amount
$135,000,000
Round
Series B
Investors
Proceeds Purpose
The financing will support advancement of Chroma's therapeutic programs toward the clinic, and continued investment in the company's core epigenetic editing platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
One Kendall Square, 1400 West
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Chroma Medicine is pioneering a new class of single-dose genomic medicines that harness epigenetics, nature's innate mechanism for gene regulation, to revolutionize treatment of disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Catherine Breen
Chief Financial Officer
Brett Kaplan
Chief Scientific Officer
Vic Myer
Browse more venture capital transactions:
Prev: 3/1/2023: Zarta venture capital transaction
Next: 3/1/2023: doctorly venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs